Nanotechnology Integrated Innovative Drug Delivery and Therapy for Cancer
Romulo R. Macadangdanga b, Rutvi Agrawalc d, Bharat Bhushane f, Akash Gargc d, Kuldeep Singhg h✉, Shivendra Kumarg h, Atul Kumarc d
- aDepartment of Nursing, College of Allied Health, National University, Manila, Philippines
- bDepartment of Nursing, College of Allied Health, National University, Philippines
- cDepartment of Pharmaceutics, Rajiv Academy for Pharmacy, Mathura, Uttar Pradesh, India
- dDepartment of Pharmaceutics, Rajiv Academy for Pharmacy, Mathura Uttar Pradesh, India
- eDepartment of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India
- fDepartment of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura Uttar Pradesh, India
- gDepartment of Pharmacology, Rajiv Academy for Pharmacy, Mathura, Uttar Pradesh, India
- hDepartment of Pharmacology, Rajiv Academy for Pharmacy, Mathura Uttar Pradesh, India
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Cancer remains a significant global health challenge, necessitating innovative approaches to enhance the efficacy and specificity of therapeutic interventions while minimizing adverse effects on healthy tissues. Nanotechnology has emerged as a promising avenue in cancer treatment, offering novel strategies for targeted drug delivery. Nanoparticles, liposomes, and polymer-based systems have played pivotal roles in revolutionizing cancer therapy. Nanotechnology possesses unique physicochemical properties, enabling efficient encapsulation of therapeutic agents and controlled and prolonged release at tumour sites. Advancement in formulations using nanotechnology has made it possible to make multifunctional systems that respond to the microenvironment of a tumour by releasing payloads in response to changes in pH, temperature, or enzymes. Stimuli-responsive polymers can release drugs in response to external cues, enabling site-specific drug release and minimizing systemic exposure. This review explores recent studies and preclinical trials that show how nanoparticles, liposomes, and polymerbased systems could be used to treat cancer, discussing challenges such as scalability, regulatory approval, and potential toxicity concerns along with patents published recently.
TL;DRThis review explores recent studies and preclinical trials that show how nanoparticles, liposomes, and polymerbased systems could be used to treat cancer, discussing challenges such as scalability, regulatory approval, and potential toxicity concerns along with patents published recently. (Semantic Scholar)